<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00888732</url>
  </required_header>
  <id_info>
    <org_study_id>Asp-BIAsp-HI-2008</org_study_id>
    <secondary_id>2008-007176-22</secondary_id>
    <nct_id>NCT00888732</nct_id>
  </id_info>
  <brief_title>A Comparison of Pharmacodynamics and Pharmacokinetics of Insulin Aspart, BIAsp70, BIAsp50 and Fast-acting Human Insulin</brief_title>
  <official_title>A Comparison of Pharmacodynamics and Pharmacokinetics of Insulin Aspart, Biphasic Insulin Aspart 70 and 50 &amp; Fast-acting Human Insulin in Patients With Type 1 Diabetes, A Randomised, Quadruple Crossover Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hypothesis is that an optimal formulation of fast acting and intermediary acting insulin
      analogues will improve post prandial glycaemic control in patients with type 1 diabetes
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial is a single centre, open-label, randomised 4 period cross-over trial, comparing
      the pk and pd profiles of IAsp, BIAsp 50, BIAsp 70 and Fast-acting Human Insulin after a
      standard test meal in subjects with type 1 diabetes. The profiles will be derived over a
      12-hour period after subcutaneous injection in the abdominal region with a single dose of
      IAsp, BIAsp 50, BIAsp 70 or Fast-acting Human Insulin at a test meal. The trial consists of a
      screening period of 4-21 days and 4 treatment visits.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmaxglu: Peak plasma glucose following test meal (breakfast). A comparison will be made between fast-acting human insulin vs. IAsp, BIAsp 50 and BIAsp 70, IAsp vs BIAsp 50 and BIAsp 70, BIAsp 50 vs. BIAsp 70.</measure>
    <time_frame>12 hours following a standard test meal (breakfast)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUCglu: The area under the plasma glucose concentration (0-12, 0-6, 6-12, 0-4, 4-8, 8-12 hours after test meal) after a single injection of one of the four insulins: IAsp, Biphasic insulin aspart 50 and 70 &amp; fast-acting human insulin</measure>
    <time_frame>12 hours following a standard test meal (breakfast)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCins: The area under insulin aspart/human insulin concentration (0-12, 0-6, 6-12, 0-4, 4-8, 8-12 hours after test meal) after a single injection of one of the four insulins: IAsp, Biphasic insulin aspart 50 and 70 &amp; fast-acting human insulin</measure>
    <time_frame>12 hours following a standard test meal (breakfast)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmaxins: Time to maximum serum insulin aspart/human insulin concentration</measure>
    <time_frame>12 hours following a standard test meal (breakfast)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum GH, total IGF-I, IGF-I bioactivity, IGFBP-1, IGFBP-2, binary complex of IGF-I, IGFBP-3 and the acid-labile subunit (ALS)</measure>
    <time_frame>12 hours following a standard test meal (breakfast)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>Insulin therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Insulin Aspart, Biphasic Insulin Aspart 70 and 50 &amp; Fast-acting Human Insulin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Aspart, BIAsp 70, BIAsp50, Human Insulin</intervention_name>
    <description>0.2 U/IU/kg subcutaneous injection, single dose</description>
    <arm_group_label>Insulin therapy</arm_group_label>
    <other_name>- Insulin Aspart: NovoRapid</other_name>
    <other_name>- BIAsp 50: NovoMix 50</other_name>
    <other_name>- BIAsp 70: NovoMix 70</other_name>
    <other_name>- Human Insulin: Actrapid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent obtained before any trial-related activities.

          -  Diagnosed type 1 diabetes before the age of 40 and on insulin treatment within one
             year of diagnosis.

          -  Insulin treatment of any regime for more than one year at time of inclusion.

          -  Total insulin demand ≥ 0,4 U/IU/kg/24 hrs

          -  HbA1c between 7% and 12% (both values included).

          -  Age ≥ 18 years.

          -  BMI between 18 and 35 kg /m2 (including both values).

        Exclusion Criteria:

          -  Known or suspected allergy to trial product(s) or related products.

          -  Recurrent major hypoglycaemic episodes.

          -  Heart: Unstable Angina Pectoris, AMI &lt; 12 months or heart insufficiency classified
             according to NYHA III-IV

          -  Blood Pressure: Severe uncontrolled hypertension with BP &gt; 180/110 mmHg, sitting

          -  Liver: Impaired hepatic function corresponding to serum-ALAT or basic phosphatase &gt; 2
             x upper reference limit of the local laboratory.

          -  Kidneys: Impaired renal function corresponding to serum-creatinin &gt; 150 μmol/l
             according to the local laboratory.

          -  Any disease judged by the investigator to affect the trial.

          -  Pregnancy, breast-feeding or the intention of becoming pregnant or fertile women not
             using adequate contraceptive measures - adequate contraceptive method is
             sterilisation, hysterectomy or current use of contraceptive pills or intra uterine
             device.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jens S Christiansen, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Aarhus</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dept of Medicine M, Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <link>
    <url>http://www.aarhussygehus.dk</url>
    <description>Click here for more information about trial site (Danish version only)</description>
  </link>
  <reference>
    <citation>Thorisdottir RL, Parkner T, Chen JW, Ejskjaer N, Christiansen JS. A comparison of pharmacokinetics and pharmacodynamics of biphasic insulin aspart 30, 50, 70 and pure insulin aspart: a randomized, quadruple crossover study. Basic Clin Pharmacol Toxicol. 2009 Mar;104(3):216-21. doi: 10.1111/j.1742-7843.2008.00355.x. Epub 2009 Jan 20.</citation>
    <PMID>19175369</PMID>
  </reference>
  <reference>
    <citation>Weyer C, Heise T, Heinemann L. Insulin aspart in a 30/70 premixed formulation. Pharmacodynamic properties of a rapid-acting insulin analog in stable mixture. Diabetes Care. 1997 Oct;20(10):1612-4.</citation>
    <PMID>9314644</PMID>
  </reference>
  <reference>
    <citation>Kang S, Creagh FM, Peters JR, Brange J, Vølund A, Owens DR. Comparison of subcutaneous soluble human insulin and insulin analogues (AspB9, GluB27; AspB10; AspB28) on meal-related plasma glucose excursions in type I diabetic subjects. Diabetes Care. 1991 Jul;14(7):571-7.</citation>
    <PMID>1914797</PMID>
  </reference>
  <reference>
    <citation>Thrailkill KM. Insulin-like growth factor-I in diabetes mellitus: its physiology, metabolic effects, and potential clinical utility. Diabetes Technol Ther. 2000 Spring;2(1):69-80. Review.</citation>
    <PMID>11467325</PMID>
  </reference>
  <reference>
    <citation>Jacobsen LV, Søgaard B, Riis A. Pharmacokinetics and pharmacodynamics of a premixed formulation of soluble and protamine-retarded insulin aspart. Eur J Clin Pharmacol. 2000 Aug;56(5):399-403.</citation>
    <PMID>11009049</PMID>
  </reference>
  <verification_date>April 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 27, 2009</study_first_submitted>
  <study_first_submitted_qc>April 27, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2009</study_first_posted>
  <last_update_submitted>April 27, 2011</last_update_submitted>
  <last_update_submitted_qc>April 27, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 28, 2011</last_update_posted>
  <responsible_party>
    <name_title>Jens Sandahl Christiansen, M.D.</name_title>
    <organization>University of Aarhus</organization>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin degludec, insulin aspart drug combination</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Aspart</mesh_term>
    <mesh_term>Insulin, Long-Acting</mesh_term>
    <mesh_term>Biphasic Insulins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

